Previously referred to as “Resochin”, Chloroquine was first discovered in 1924 at Bayer laboratories. Its first use was initially ignored as it was found to be toxic to people. What if plaquenil doesn't work for lupus Plaquenil suddenly stopping and mania For example, chloroquine-resistant malaria is widespread in sub-Saharan Africa, including Nigeria, and resistance to sulfadoxine-pyrimethamine also occurs in this region. Chloroquine is the drug of choice for people who travel to these areas; however, resistance to chloroquine is now widespread in all areas of the world where malaria is endemic, but it is still an. Chloroquine, used at recorded levels 190 tons hundreds of millions of treatment courses in Africa alone each year, has been a tremendous force driving the widespread replacement of chloroquine-sensitive by chloroquine-resistant P. falciparum. These trials showed that chloroquine eliminated malaria and was appropriate to be used as an antimalarial drug. Thus, it was not until World War II that the government of the United States sponsored the clinical trials of chloroquine as an antimalarial drug. Chloroquine-resistant malaria is now widespread in africa Malaria Travel & Health Guide, 2019 Online Book, Recommended Malaria Prophylaxis for Travelers Hydroxychloroquine tablet ip 200 mgHydroxychloroquine 25mg CDC continues to monitor the status of chloroquine-resistant P. falciparum malaria in East Africa 2. Recent reports document that the transmission of resistant parasites is now occurring more widely in Africa than was previously described 2. Update Chloroquine-Resistant Plasmodium falciparum -- Africa. Chloroquine-Resistant Malaria The Journal of Infectious.. Malaria Drug Resistance Worldwide Antimalarial.. If artemisinin resistance becomes widespread in Africa, as has happened with other antimalarial drugs such as chloroquine, then the public health consequences would be catastrophic and it is likely there would be a reversal in the recent declines seen in malaria mortality. Antimalarial drug use in Africa. Malaria remains an overwhelming problem in Africa, where about 90% of global malaria morbidity and mortality occur. 1 In most of sub-Saharan Africa, the majority of cases are caused by Plasmodium falciparum, the most virulent human malaria parasite, and the parasite with the greatest likelihood of drug resistance. Chloroquine has long been used in the treatment or prevention of malaria from Plasmodium vivax, P. ovale, and P. malariae, excluding the malaria parasite Plasmodium falciparum, for it started to develop widespread resistance to it.